Concordia International Corp.

Concordia International Corp.

Concordia International Corp.

Overview
Date Founded

2010

Headquarters

277 Lakeshore Road East,Suite 302,Oakville, ON L6H 1J9

Type of Company

Public

Industries

Pharmaceuticals

Company Description

Concordia International Corp. is an integrated, specialty healthcare company that focuses on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. It engages in the development of pharmaceutical products and medical devices. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in Oakville, Canada.

Executives & Employees

Chief Executive Officer & Director

Chief Financial Officer

Secretary & Chief Legal Officer

Chief Corporate Development Officer

President, North America Segment

President-International Segment

Subscribe now to see full list of current and former executives
Board of Directors

Former Partner at JJR Private Capital, Inc.

Chief Financial Officer-Life Sciences at Dickinson & Co.

Former Executive Vice President, Finance & Administration & Chief Financial Officer at Forest Laboratories, Inc.

Senior Partner at Deeth Williams Wall LLP

Chief Executive Officer & Director at Concordia International Corp.

Advisor at Telephus Biosciences

Former Chairman at Teva Pharmaceutical Industries Ltd.

Subscribe now to see full list of current and former board members
Paths to Concordia International Corp.
Potential Connections via
Relationship Science
You
Concordia International Corp.
Recent Transactions
Details Hidden

Concordia International Corp. purchases Concordia International RX (UK) Ltd. from Cinven Group Ltd., AlpInvest Partners BV

Details Hidden

Concordia International Corp. issued Common Stock

Details Hidden

Concordia International Corp. issued Subscription Receipts

Subscribe now to see full list of recent transations
Transaction Advisors
Legal Advisor

Advised onConcordia International Corp. purchases Concordia International RX (UK) Ltd. from Cinven Group Ltd., AlpInvest Partners BV

Auditor

Advised onConcordia International Corp. issued Common Stock

Escrow Agent

Advised onConcordia International Corp. issued Common Stock

Subscribe now to see 18+ more transaction advisors
Legal Advisor

Advised onConcordia International Corp. purchases Concordia International RX (UK) Ltd. from Cinven Group Ltd., AlpInvest Partners BV

Director

Advised onConcordia International Corp. issued Common Stock

Legal Advisor

Advised onConcordia International Corp. purchases Concordia International RX (UK) Ltd. from Cinven Group Ltd., AlpInvest Partners BV

Subscribe now to see 30+ more transaction advisors
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Advisor

Former Chief Financial Officer, Secretary & Treasurer at Concordia International Corp.

Subscribe now to see advisors & consultants for over 2.5 million organizations
Clients

Knight Therapeutics Inc acquires, sells and markets prescription and over-the-counter pharmaceutical products. It offers commercialized Rx and OTC products, which includes Impavido, Movantik, Neuragen and Flat Tummy Tea. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Saudi Chemical Co. engages in the manufacture and trade of chemical. It operates through the following segments: Explosives, Medicines and Detergents, and Production of Ammonium Nitrate. Its products include electronic detonators, blasting agents, initiation systems, seismic explosives, and accessories. The company was founded on March 25, 1972 and is headquartered in Riyadh, Saudi Arabia.

Recordati SpA engages in the research, development, manufacturing, and marketing of pharmaceuticals. It operates through two segments: Pharmaceutical and Rare Diseases. The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and active ingredients for its proprietary and licensed brands. The Rare Diseases segment develops, produces, and sells orphan drugs for the treatment of uncommon metabolic deficiencies of a genetic nature. The company was founded by Giovanni Recordati in 1926 and is headquartered in Milan, Italy.

Subscribe now to see clients for over 2.5 million organizations
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$46.2M
Total Enterprise Value
$4.37B
Earnings Per Share
$-34.17
Revenue
$1.08B
Net Profit
$-1.74B
EBITDA
$580M
EBITDAMargin
53.59%
Total Debt
$4.76B
Total Equity
$-506M
Enterprise Value Sales
4.04x
Enterprise Value EBITDAOperating
7.54x
TEVNet Income
-2.51x
Debt TEV
1.09x
Three Year Compounded Annual Growth Rate Of Revenue
172.24%
Subscribe now to see full financial details
Suppliers
Shionogi & Co., Ltd. Wholesale: Consumer Non-Durables/Sundries | Tokyo, TY

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Consort Medical Plc Hospitals & Patient Services | Hemel Hempstead, HD

Consort Medical Plc engages in the design, development, manufacture, and sale of medical drug delivery devices. It operates through two segments: Bespak and Aesica. The Bespak segment develops and produces drug delivery devices, which serves pharmaceutical companies with inhaler and auto-injector technologies. The Aesica segment is a contract development and manufacturing organization which serves pharmaceutical firms with active pharmaceutical ingredient and finished dose formulation development and manufacturing services. The company was founded on March 22, 1946 and is headquartered in Hemel Hempstead, United Kingdom.

Cenexi SASU Pharmaceuticals | Fontenay-sous-Bois, IF

Cenexi SASU specializes in the contract manufacturing of pharmaceuticals for humans and veterinary markets. It also manufactures solid forms (tablets and capsules), syrups, suppositories and parental ampoules for the world market. The company was founded in 2004 and is headquartered in Fontenay-sous-Bois, France.

Subscribe now to see 3 more suppliers
Competitors
Impax Laboratories, Inc. Pharmaceuticals - Hayward, CA

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture, and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments. The Impax Generics segment concentrates on the development manufacture, sale and distribution of generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Impax Specialty Pharma segment engages in the development of proprietary brand pharmaceutical products. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

The Medicines Co. Pharmaceuticals - Parsippany, New Jersey

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Hikma Pharmaceuticals Plc Pharmaceuticals - London, GL

Hikma Pharmaceuticals We are committed to improving people’s lives. Through our existing products and pending approvals across our markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas. Our vision Our vision is to build Hikma into a world class and leading specialty pharmaceutical company, with presence across the globe. Through organic growth and by acquisitions which are aligned with our strategy, we will continue to develop the business and maintain the high standards of ethics and responsibility which are central to the way we operate.